Talk:Cabergoline: Difference between revisions

(5 intermediate revisions by 5 users not shown)

Line 1:

{{headerpanel|{{Stub}}}}

~~[[File:~~Cabergoline~~.svg|300px|thumbnail|The structure of cabergoline]]~~

'''Cabergoline''' is a chemical of the [[lysergamide]] and ergopeptine classes. It is a derivative of [[LSD]] or more specifically [[AL-LAD]] ~~and~~ shares many effects with related, non-psychedelic compounds such as [[ergotamine]], ergonovine or [[lisuride]]. It is occasionally prescribed to treat symptoms of high prolactin levels and managing Parkinson's disease.

'''Cabergoline''' is a chemical of the [[lysergamide]] and ergopeptine classes. It is a close derivative of [[LSD]], more specifically, [[AL-LAD]], but instead shares many effects with related, non-psychedelic medicinal compounds such as [[ergotamine]], ergonovine or [[lisuride]]. It is occasionally prescribed to treat symptoms of high prolactin levels and managing Parkinson's disease.

Cabergoline is not predominantly psychedelic ~~but rather~~ exerts its effects ~~strongest~~ at the [[dopamine]] D2 receptor as an agonist ~~and~~ comparatively little on the [[serotonin]] 5-HT2A receptor, as a partial agonist.

Cabergoline is not predominantly psychedelic, it mainly exerts its effects at the [[dopamine]] D2 receptor as an agonist but has comparatively little effect on the [[serotonin]] 5-HT2A receptor where it acts as a partial agonist.

Cabergoline has little recreational value ~~exclusively due to~~ its unique property of reducing or eliminating the male refractory period, ~~thereby~~ allowing men to experience multiple ejaculatory orgasms in rapid succession.<ref>Krüger TH, Haake P, Haverkamp J, ~~et al~~. (~~December 2003~~). "Effects of acute prolactin manipulation on sexual drive and function in males~~". Journal of Endocrinology.~~ 179 (3~~): 357–65. CiteSeerX 10.1.1.484.4005.~~ doi:10.1677/joe.0.1790357~~. PMID 14656205.~~</ref><ref>Hollander, ~~Adam~~ B.; Pastuszak, ~~Alexander~~ W.; Lipshultz, ~~Larry~~ I. ~~(2016~~)~~. "~~Cabergoline in the Treatment of Male Orgasmic ~~Disorder—A~~ Retrospective Pilot Analysis~~". Journal of Sexual Medicine.~~ 4 ~~(4): e28–e33.~~ doi:10.1016/j.esxm.2015.09.001~~. PMC 4822480. PMID 26944776.~~</ref>

Cabergoline has little recreational value other than its unique property of reducing or eliminating the male refractory period, allowing men to experience multiple ejaculatory orgasms in rapid succession.<ref>{{cite journal | vauthors=((Krüger, T. H. C.)), ((Haake, P.)), ((Haverkamp, J.)), ((Krämer, M.)), ((Exton, M. S.)), ((Saller, B.)), ((Leygraf, N.)), ((Hartmann, U.)), ((Schedlowski, M.)) | journal=The Journal of Endocrinology | title=Effects of acute prolactin manipulation on sexual drive and function in males | volume=179 | issue=3 | pages=357–365 | date= December 2003 | issn=0022-0795 | doi=10.1677/joe.0.1790357}}</ref><ref>{{cite journal | vauthors=((Hollander, A. B.)), ((Pastuszak, A. W.)), ((Hsieh, T.-C.)), ((Johnson, W. G.)), ((Scovell, J. M.)), ((Mai, C. K.)), ((Lipshultz, L. I.)) | journal=Sexual Medicine | title=Cabergoline in the Treatment of Male Orgasmic Disorder-A Retrospective Pilot Analysis | volume=4 | issue=1 | pages=e28-33 | date= March 2016 | issn=2050-1161 | doi=10.1016/j.esxm.2015.09.001}}</ref>

==See also==

*[[Responsible use]]

*[[Lysergamide]]

Line 14:

Line 16:

==External links==

*[https://en.wikipedia.org/wiki/Cabergoline Cabergoline (Wikipedia)]

*[https://isomerdesign.com/PiHKAL/explore.php?id=9594&name=Cabergoline Cabergoline (Isomer Design)]

Line 20:

Line 23:

[[Category:Alkaloid]]

[[Category:Lysergamide]]

@@ Line 1: / Line 1: @@
 {{headerpanel|{{Stub}}}}
-[[File:Cabergoline.svg|300px|thumbnail|The structure of cabergoline]]
+{{SummarySheet}}
-'''Cabergoline''' is a chemical of the [[lysergamide]] and ergopeptine classes. It is a derivative of [[LSD]] or more specifically [[AL-LAD]] and shares many effects with related, non-psychedelic compounds such as [[ergotamine]], ergonovine or [[lisuride]]. It is occasionally prescribed to treat symptoms of high prolactin levels and managing Parkinson's disease.
+{{SubstanceBox/Cabergoline}}
+'''Cabergoline''' is a chemical of the [[lysergamide]] and ergopeptine classes. It is a close derivative of [[LSD]], more specifically, [[AL-LAD]], but instead shares many effects with related, non-psychedelic medicinal compounds such as [[ergotamine]], ergonovine or [[lisuride]]. It is occasionally prescribed to treat symptoms of high prolactin levels and managing Parkinson's disease.
-Cabergoline is not predominantly psychedelic but rather exerts its effects strongest at the [[dopamine]] D<sub>2</sub> receptor as an agonist and comparatively little on the [[serotonin]] 5-HT<sub>2A</sub> receptor, as a partial agonist.
+Cabergoline is not predominantly psychedelic, it mainly exerts its effects at the [[dopamine]] D<sub>2</sub> receptor as an agonist but has comparatively little effect on the [[serotonin]] 5-HT<sub>2A</sub> receptor where it acts as a partial agonist.
-Cabergoline has little recreational value exclusively due to its unique property of reducing or eliminating the male refractory period, thereby allowing men to experience multiple ejaculatory orgasms in rapid succession.<ref>Krüger TH, Haake P, Haverkamp J, et al. (December 2003). "Effects of acute prolactin manipulation on sexual drive and function in males". Journal of Endocrinology. 179 (3): 357–65. CiteSeerX 10.1.1.484.4005. doi:10.1677/joe.0.1790357. PMID 14656205.</ref><ref>Hollander, Adam B.; Pastuszak, Alexander W.; Lipshultz, Larry I. (2016). "Cabergoline in the Treatment of Male Orgasmic Disorder—A Retrospective Pilot Analysis". Journal of Sexual Medicine. 4 (4): e28–e33. doi:10.1016/j.esxm.2015.09.001. PMC 4822480. PMID 26944776.</ref>
+Cabergoline has little recreational value other than its unique property of reducing or eliminating the male refractory period, allowing men to experience multiple ejaculatory orgasms in rapid succession.<ref>{{cite journal | vauthors=((Krüger, T. H. C.)), ((Haake, P.)), ((Haverkamp, J.)), ((Krämer, M.)), ((Exton, M. S.)), ((Saller, B.)), ((Leygraf, N.)), ((Hartmann, U.)), ((Schedlowski, M.)) | journal=The Journal of Endocrinology | title=Effects of acute prolactin manipulation on sexual drive and function in males | volume=179 | issue=3 | pages=357–365 | date= December 2003 | issn=0022-0795 | doi=10.1677/joe.0.1790357}}</ref><ref>{{cite journal | vauthors=((Hollander, A. B.)), ((Pastuszak, A. W.)), ((Hsieh, T.-C.)), ((Johnson, W. G.)), ((Scovell, J. M.)), ((Mai, C. K.)), ((Lipshultz, L. I.)) | journal=Sexual Medicine | title=Cabergoline in the Treatment of Male Orgasmic Disorder-A Retrospective Pilot Analysis | volume=4 | issue=1 | pages=e28-33 | date= March 2016 | issn=2050-1161 | doi=10.1016/j.esxm.2015.09.001}}</ref>
 ==See also==
 *[[Responsible use]]
 *[[Lysergamide]]
@@ Line 14: / Line 16: @@
 ==External links==
 *[https://en.wikipedia.org/wiki/Cabergoline Cabergoline (Wikipedia)]
 *[https://isomerdesign.com/PiHKAL/explore.php?id=9594&name=Cabergoline Cabergoline (Isomer Design)]
@@ Line 20: / Line 23: @@
 [[Category:Alkaloid]]
 [[Category:Lysergamide]]
+<references />